CClinicalTrials.gg
Sign In
TerminatedNCT01215578NETUpdated Apr 30, 2015

Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors

A Phase 2 interventional study of Sutent in Neuroendocrine Tumors, Pancreatic Neoplasms and Advanced Disease, sponsored by Assistance Publique - Hôpitaux de Paris. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-04-30.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 2, Interventional, and Treatment

Why this study was terminated
lack of recruitement
Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to identify predictive molecular markers of response to continuous daily sunitinib at dose of 37.5 mg used in patients with poorly-differentiated Advanced/Inoperable NEURO-Endocrine Tumors.

Hypothesis:

  • To distinguish molecular markers based on their expression at the initial biopsy, their detection by proteomic analysis and demonstrating that tumor or vascular cells are straightaway sensitive to sunitinib (markers sensitivity).
  • The presence of these markers at the initial biopsy predict the sensitivity to sunitinib(Positive predictive value of markers)
Read the detailed description

Neuroendocrine tumors (NET) are rare malignancies (1-2% of digestive cancers); and there is, in recent years, a slow but steady increase in their incidence. Despite the joint efforts of several research groups, which led to the new WHO classification (2002), the natural history of the disease remains heterogene and the resistance to conventional cytotoxic treatment remains the common denominator of these tumors.

Indeed, the prognosis of patients with metastatic disease remains poor despite numerous treatments (including: IFN, DTIC, 5-FU, doxorubicin, somatostatin analogues, etc.).

None of which showed a benefit in terms of survival. The main therapeutic objective is still to get a palliative effect on the symptoms and / or limit a few months tumor progression.

There are many publications showing that angiogenesis is one of the major mechanisms of tumor progression in TNE. But the multiple signaling pathways involved, the existence of alternative routes and their relationship to apoptosis inducing molecules remain unknown. Sunitinib is a new molecule in the family of tyrosine kinase inhibitors targeting multiple receptors which VEGFR, KIT, PDGF-R, FLT3 and RET. Since 2006 year, Sunitinib has been approved to treat advanced kidney cancer also called advanced renal cell carcinoma (a typically chemoresistant disease for which there was no active treatment available).

Many retrospective studies in patients showing that the TNE overexpress one or more targets of sunitinib. In Phase I trial, an antitumor activity has been identified in neuroendocrine tumors. In a phase II trial including 100 patients with well-differentiated TNE and carcinoids, sunitinib is associated with a response rate of 10%, and 82% of clinical benefit in the form of tumor stability.

Currently, an international randomised phase III trial initiated in well differentiated forms, but no studies are underway for poorly-differentiated TNE.

All of this suggests that sunitinib could represent an important therapeutic option for moderate, or poorly differentiated inoperable TNE and needs to be explored in this pathology by identifying predictive biomarkers of response.

02

Conditions studied

  • Neuroendocrine Tumors
  • Pancreatic Neoplasms
  • Advanced Disease
  • Sunitinib

Keywords

  • Neuroendocrine Tumors
  • Neuroectodermal Tumors
  • Neoplasms, Germ Cell and Embryonal
  • Neoplasms by Histologic Type
  • Neoplasms
  • Neoplasms, Glandular and Epithelial
  • Neoplasms, Nerve Tissue
  • Pancreatic Neoplasms
  • Digestive System Neoplasms
  • Neoplasms by Site
  • Endocrine Gland Neoplasms
  • Adenoma, Islet Cell
  • Adenocarcinoma
  • Carcinoma
  • Adenoma
  • Digestive System Diseases
  • Pancreatic Diseases
  • Endocrine System Diseases
  • Sunitinib
  • Antineoplastic Agents
  • Therapeutic Uses
  • Pharmacologic Actions
  • Angiogenesis Inhibitors
  • Angiogenesis Modulating Agents
  • Growth Substances
  • Physiological Effects of Drugs
  • Growth Inhibitors
03

In context

Neoplasms

9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.

This study's enrollment of 33 is below the median of 50 across 7,253 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,505 studies on the registry; 1,006 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Digestive NET histopathologically proven, poorly-differentiated
  • Inoperable/advanced NET (Tumor relapse inoperable or metastatic with no surgical indication).
  • Tumor samples should be made available for analysis(diagnostic biopsy, surgical specimen)

  • measurable disease defined by at least one lesion wich can be measured by at least one dimension :

    • equal or superior to 20 mm ( by conventional methods )
    • equal or superior to 10 mm (by spiral scan within 28 days before the beginning of the treatment)
  • Performance status WHO ≤ 2.

  • Adequate organ function :

    • hematology (absolute neutrophil count equal or superior to 1,5 x 10*9/l , platelet equal or superior to 100 x 10*9/l),
    • clearance of creatinine equal or superior to 60 ml/min),
    • AST/ALT ≤ 5 N, PAL ≤ 5 N, total bilirubin ≤ 2N.
  • the selected women must be post-menopausal woman or surgically castrated or have to accept an effective contraception for the duration of the treatment and 3 month after.Women who are old enough to procreate must have a negative pregnancy test within the 72 hours of the beginning of the treatment.They must not be pregnant or to breastfeed.the selected men and theirs partners must be sterile or use an effective contraception for the duration of the treatment and 3 month after.

Exclusion criteria

Exclusion Criteria:

  • Hypersensitivity to sunitinib.
  • Contraindication to sunitinib, including uncontrolled hypertension, medical history of cerebrovascular accident, unstable cardiac pathology despite optimal medical therapy (myocardial infarction within the 6 months prior to study drug administration, severe/unstable angina ), active hemorrhagic syndrome or concomitant treatment with anticoagulants.
  • Any severe acute or chronic co-morbid that may compromise to comply with study participation: uncontrolled infection, symptomatic congestive heart failure, liver disturbance, chronic renal failure, active gastro-duodenal ulcer (nonexhaustive list).
  • Known brain metastases.
  • Diagnosis of any second malignancy within the last 3 years, except for basal cell or squamous cell skin cancer, or in situ carcinoma of the cervix uteri
  • Current treatment on another clinical trial.
  • Prior treatment with an investigational agent within 4 weeks.
  • Prior treatment with intravenous biphosphonates
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    patient treated

    patient who receive sunitinib (SUTENT)

    Drug: Sutent

Interventions

  • DrugSutent

    sunitinib 37.5 mg/day (per os) for 6 months

06

What researchers measure

Primary outcomes

  1. Predictive molecular markers of response to sunitinib

    to assess the correlation between the expression of biomarkers and CT scan response. Patients are considered as responders when objective response (Partial or complete response) is showed on CT scan.

    Time frame: 1 year

Secondary outcomes

  1. The antitumor activity of sunitinib

    * Objective response according to RECIST criteria (Time Frame: duration of study Safety issue: No). * Overall Survival (Time Frame: 6 months. Safety issue: No). * Progression-free survival (PFS) * Correlation between overall survival, PFS and tumor necrosis assessed on CT scan

    Time frame: 1 year

  2. Residual concentration

    correlation between the concentration of sunitinib and its major active metabolite, SU012662, and objective response and /or toxicity.

    Time frame: 2 months

07

Study locations

1 site
  • Hôpital Beaujon
    Clichy, Hauts de Seine 92110, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 30, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01215578
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Responsible party
Sponsor
First posted
Oct 6, 2010
Start date
Oct 2008
Primary completion
Dec 2013
Completion
Dec 2014
Last update
Apr 30, 2015

Study contacts

Eric Raymond, Professor
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Neoplasms→

Other studies from this sponsor

Assistance Publique - Hôpitaux de Paris

Start the discussion